ESTRO 2023 - Abstract Book

S1093

Digital Posters

ESTRO 2023

Fifty patients with liver metastases were included ( table 1 ). Median follow-up was 24 months. A relationship between time to relapse and BED10Gy within treatment groups was observed (p = 0.025). Median LC was 29 months, in the ≤ 100 Gy and >100 Gy group were 30 months (13,8-46,2) and 23 months (13,8-34,1) respectively (p = 0.505). Median OS was 24 months, in the ≤ 100 Gy and >100 Gy group were 22 months (16,4-27,5) and 34 months (20,0-47,9) respectively (p = 0.07) ( Figure 1 ). In multivariable Cox regression analyses, group dose and tumor volume were correlated with LC and OS but no significant differences were found

Conclusion High dose SBRT (BED10Gy >100) provides difference close to statistical significance for OS than low dose SBRT. No significant differences have been found for local control.

PO-1364 stereotactic radiotherapy for oligometastatic esophagogastric carcinoma outcome, prognostic factors

L. Di Cristina 1,2 , D. Franceschini 1 , M.A. Teriaca 1 , V. Vernier 1,2 , L. Lo Faro 1,2 , C. Franzese 1,2 , T. Comito 1 , E. Clerici 1 , L. Bellu 1 , L. Dominici 1 , R. Spoto 1 , M. Massaro 1 , P. Navarria 1 , M. Scorsetti 1,2 1 IRCCS Humanitas Research Hospital, Radiotherapy and Radiosurgery, Rozzano – Milan, Italy; 2 Humanitas University, Biomedical Sciences, Pieve Emanuele – Milan, Italy Purpose or Objective The aim of this study was to evaluate clinical results and prognostic factors in a cohort of patient with oligometastatic esophagogastric adenocarcinoma treated with SRT.

Materials and Methods